# Lingke Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lingke-pharmaceutical-co

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.lynkpharma.com
- Total disclosed funding: $115M
- Latest round: Series C (Sep 21, 2023)
- Investors on record: 15

## About

Based in Zhejiang, China, and founded in 2017, Lynk Pharmaceuticals Co., Ltd. is a clinical-stage developer of novel medicines. The company was co-founded by Dr. Zhao-Kui Wan, Dr. Jun Wang, Dr. Michael Vazquez, and Mr. Jarod Chen. In 2020, the company had out-licensed a preclinical drug candidate to an American company and obtained a licensed RAS inhibitor from Kobe university & RIKEN research institute in Japan. In May 2023, Lynk Pharmaceuticals Co., Ltd. raised CNY 200 million in series C funding from new investors China Grand Prosperity Investment, Tailong Capital, and Liando Investment. In September 2023, the firm raised CNY 122 million in series C+ funding from new investors Haibang Venture, HowBuy Wealth Management, returning investors CGP Investment, Lilly Asia Ventures, and New Alliance Capital.

Lynk Pharmaceuticals' research and development techniques are used in Oncology, Immune inflammation, PROTAC, and Virtual screens. The company's pipeline products include Immune 1 to 4 an FIC and BIC/FIC potential, Oncology 1 to 3, an FIC potential, RAS, an FIC potential, and PROTAC or Novel Targets, an FIC potential.

The company plans to conduct Phase I and II clinical trials for multiple programs in the research and development pipeline.

## Funding rounds

- Series C, Sep 21, 2023, $17M — Lilly Asia Ventures, CGP Investment, New Alliance Capital, Haibang Venture, HowBuy Wealth Management
- Series C, May 31, 2023, $28M — Prosperity Investment, Liandong Group, Tailong VC
- Series B, Aug 27, 2021, $50M — Legend Capital, Lilly Asia Ventures, New Alliance Capital, MED-FINE Capital, HEDA Ventures
- Series A, Jan 4, 2021, $20M — Legend Capital
- Series A, Apr 17, 2020 — Kaitai Capital, Decheng Capital, MED-FINE Capital, Zheshang Group
- Angel, Apr 25, 2018 — Kaitai Capital, Shanghai Jianyi Private Equity Fund Management, MED-FINE Capital

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Angel, Series A
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Angel
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Angel, Series A, Series B
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A
- Zheshang Group (https://capitalatlas.ai/funds/zheshang-group) — Series A
- Legend Capital — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B, Series C
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series B, Series C
- HEDA Ventures (https://capitalatlas.ai/funds/heda-ventures) — Series B
- Prosperity Investment — Series C
- Liandong Group — Series C
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series C
- CGP Investment — Series C
- Haibang Venture — Series C
- HowBuy Wealth Management — Series C